Episode 4 of Supply Chain Signal examines PhRMA’s legal challenge to CMS ’ GLOBE model and whether manufacturers can lower costs, expand U.S. production and strengthen supply chain resilience all at once.
|Articles|March 20, 2023
PAP 2023: Vijesh Unnikrihnan Discusses Taking a Digital-First Approach Presentation at Access PAP 2023
ZS exec offers a synopsis of his 'Taking a Digital-First Approach to Solving the Fragmented Support Service Experience' discussion at day one of the conference.
Advertisement
In an interview with Pharma Commerce Editor, Nicholas Saraceno, Vijesh Unnikrihnan, digital health strategy lead, ZS, talks taking a digital-first approach at Access PAP 2023.
Advertisement
Related to this article
Cencora’s Matt Sample and Gregg Gorniak explain why AI should recommend, not decide, and why pharma needs an agent strategy before chasing use cases.
CSafe's Aaron Mantia explains how lane, temperature range, duration and product cost shape thermal protection choices for bulk air cargo.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how automation cuts human touches, enforces quarantine and consolidates cold storage.
PAXAFE's Mark Talens explains why real-time visibility starts with process redesign and how it speeds cold chain disposition decisions.
At LogiPharma USA 2026, Cold Chain Technologies' Anthony "TJ" Rizzo discusses cold chain expertise gaps and how data tools are reshaping the profession.
Zoomlogi's Henry Ames explains how AI agents and digitized SOPs help quality managers decide on quarantine or release after a cold chain excursion.
At LogiPharma USA 2026, Cold Chain Technologies' Vijay Paliwal explains how predictive monitoring and right-sized packaging cut excursion risk and waste.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Inside the 340B Rebate Pilot Standoff: Court, Congress, Drugmakers
2
Pharma Pulse: Cencora to Acquire AON, Amazon and Google Back ePA Expansion
3
Is Pharma Moving Too Fast on AI Agents?
4
Supply Chain Signal: PhRMA’s GLOBE Lawsuit and the New Economics of Pharma Supply Chains
5